Generi Biotech Kits
search
  • Generi Biotech Kits
  • Generi Biotech Kits

CE IVD Real-Time PCR Kits For Pharmacogenetics

Reference: PHARM

A range of kits that are used for in vitro genotypization before an appropiate treatment of disease starts.

Features :

  • Complete PCR kits with ready-to-use reagents
  • Uniform cycling program for all assays
  • High sensitivity and specificity

High flexibility and easy handling

  • Standard PCR cycling program for all assays
  • Complete PCR kits with ready to use reagents
  • Positive control provided with each assay

Safe diagnosis

  • Full range of CE IVD kits
  • Excellent analytical performance; high sensitivity and specificity
  • Increased safety by using an internal control for monitoring RNA/DNA extraction and PCR inhibition

Flexible and compatible

  • Compatible with most common real-time PCR cyclers
  • Compatible with different DNA/RNA extraction methods
  • Validated on Roche LightCycler® 480, Qiagen Rotor Gene®Q, Bio-Rad CFX96™
  • Compatible with Thermo QuantStudio™5 Dx, Mic (Bio Molecular Systems)

Real-Time PCR Kits

Kit Name Description Cat#
gb PHARM TPMT TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C
Thioguanine and mercaptopurine (antitumor drugs - hematooncology)
Before initiating treatment with azathioprine (immunosuppressant)
3217
gb PHARM DPYD*2A DPYD*2A
Before initiating treatment with fluoropyrimidine chemoterapeutics (5-fluorouracil)
3210
gb PHARM DPYD *2A(c1905+1G>A), *13(c1679T>G), HapB3(c1236G>A), c2846A>T
Before initiating treatment with fluoropyrimidine chemoterapeutics (5-fluorouracil)
3255
gb PHARM Warfarin CYP2C9*2, CYP2C9*3, G1639A, VKORC1
Before initiating treatment with warfarin
3250
gb PHARM CYP2C19 CYP2C19*2, CYP2C19*3, CYP2C19*17
Before initiating treatment with anticoagulants (clopidogrel)
Treatment with antidepressants and antimycotics
3254
gb PHARM UGT1A1 5TA/6TA/7TA/8TA
Before initiating treatment with irinotecan and atazanavir
Gilbert's syndrome
Hyperbilirubinemia
3253
gb PHARM BCHE A (D70G, rs1799807), K (A539T, rs1803274), F1 (T243M, rs28933389), F2 (G390V, rs28933390), S1 (FS117, rs398124632)
In patients diagnosed with genetic alterations in the BCHE gene, it is recommended to use alternative agents to myorelaxants suxamthonium and mivacurium
3256

Our website uses cookies to improve your user experience. By continuing to browse this website and clicking the CLOSE button, you declare to accept the use of cookies. LEARN MORE about how cookies are used on this website.
Product added to cart!